Stockscreener 앱 받기
2.05
7.24%
-0.16
시간 외 거래:
2.08
0.03
+1.46%
Vor Biopharma Inc 주식(VOR)의 최신 뉴스
What analysts say about Vor Biopharma Inc. stockSpectacular growth rates - Autocar Professional
Vor Biopharma Inc. Stock Analysis and ForecastSuperior stock growth - Autocar Professional
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - Stock Titan
Is Vor Biopharma Inc. a good long term investmentExplosive portfolio gains - jammulinksnews.com
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target - MSN
What drives Vor Biopharma Inc. stock priceExceptional trading performance - Jammu Links News
Vor Biopharma's Strategic Turnaround and the Case for Immediate Investment - AInvest
Vor Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Bio Awards Massive 5.3M Share Package to New Development Chief: Full Grant Details Revealed - Stock Titan
Vor Biopharma shares rise 2.52% premarket after appointing Qing Zuraw as Chief Development Officer. - AInvest
Why Vor Biopharma Inc. stock is on top investor watchlistsFree Real-Time Market Predictions - Newser
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer - Yahoo Finance
Vor Biopharma Faces Crucial Market Shifts Amid Latest Developments - StocksToTrade
Vor Biopharma Stock Faces Volatile Week Amid Mixed Financial Reports - timothysykes.com
Vor Biopharma Inc. shares rise 2.00% premarket after Bonesupport CEO predicts strong growth. - AInvest
How Vor Biopharma Inc. stock performs during market volatilitySafe Entry High Exit Alerts - Newser
What makes Vor Biopharma Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
Why Vor Biopharma Inc. stock attracts strong analyst attentionBreakout Confirmation Tool - newser.com
Vor Biopharma Stock’s Rollercoaster: Time to Buy? - StocksToTrade
VOR’s 2025 Market Dance: Up 174.66% – Time to Invest? - investchronicle.com
Vor Biopharma Explodes 22% – What’s Fueling the Surge? - AInvest
Vor Biopharma Names Sandy Mahatme as CFO, Chief Business Officer - MarketScreener
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer - The Manila Times
Vor Bio Strengthens Leadership: Top Biotech Executive Who Raised $6B Joins as New CFO/CBO - Stock Titan
Vor Biopharma shares rise 5.83% intraday after $41B telitacicept licensing deal and HC Wainwright upgrade. - AInvest
Vor Biopharma Sees Unusually High Options Volume (NYSE:VOR) - Defense World
Vor Biopharma Shares Soar 23.22% on Analyst Upgrades - AInvest
Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants - Seeking Alpha
VOR’s Unexpected Surge: What’s Driving the Spike? - timothysykes.com
VOR Biopharma Inc. Faces Uncertain Future Amid Recent Developments - StocksToTrade
Vor Biopharma Soars 19.1% on Analyst Upgrade - AInvest
Vor Biopharma Stock Skyrockets: What’s Next? - StocksToTrade
Vor Biopharma shares surge 28.01% intraday after licensing telitacicept for autoimmune diseases and raising $1.75B in private funding. - AInvest
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Vor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by HC Wainwright - Defense World
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Massive CEO Stock Grant: Vor Bio Awards 83M Shares to New Chief Executive at $0.89 - Stock Titan
0.87%
0.17%
자본화:
|
볼륨(24시간):